Cardiovascular Protection After Preeclampsia With Enalapril
Women and Infants Hospital of Rhode Island
Summary
The purpose of this study is to learn if postpartum women are willing to be randomized to different blood pressure medicines after delivery and how that affects blood pressure in women with hypertensive disorders of pregnancy.
Description
Cardiovascular disease (CVD) is the leading cause of death in women worldwide, and despite declines in all other age groups, mortality rates attributed to CVD are increasing in women of childbearing age. Hypertensive disorders of pregnancy (HDP), including preeclampsia and gestational hypertension, are well-established risk factors for CVD across diverse patient populations. There is compelling evidence that the preponderance of HDP-associated CVD risk is linked to progression to chronic hypertension following pregnancy. Thus, the postpartum period after HDP is a critical yet under-studied opp…
Eligibility
- Age range
- 18+ years
- Sex
- Female
- Healthy volunteers
- No
Inclusion Criteria: * Postpartum individuals * ≥18 years old * Hypertensive disorder of pregnancy * Enrolled in Women and Infants Hospital Hypertension Equity remote monitoring program. Exclusion Criteria: * Maternal cardiac disease * Individuals with pre-pregnancy hypertension or diabetes * Allergy or contraindication to enalapril
Interventions
- DrugEnalapril
First-line anti-hypertensive treatment with enalapril
- OtherStandard treatment
First-line anti-hypertensive treatment per standard of care
Location
- Women and Infants HospitalProvidence, Rhode Island